Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!

Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.

GlaxoSmithKline (GSK) is currently conducting a Phase 4 clinical study titled ‘A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered ...

PHILADELPHIA, June 24, 2025--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte ...

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

A handful were on belimumab (Benlysta) as well as anifrolumab. Those on versus not on valaciclovir were generally similar, except for history of previous zoster attacks.

Belimumab demonstrated superior efficacy vs placebo for achieving remission and low disease activity status among patients with active SLE.

HealthDay News — The US Food and Drug Administration has approved a 200 mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic ...